Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder

Ki vehet részt

• Patients with BED according to DSM-5
• Male or female patients aged between 18 and 40 (the upper age limit was chosen to minimise potential confounding effects by hormonal changes related to menopause)
• Written informed consent obtained according to international guidelines and local laws
• Ability to understand the nature of the trial and the trial related procedures and to comply with them

Ki nem vehet részt

• current or planned use of psychotropic medication (during the period of the study)
• current diagnosis of a psychotic, bipolar, or substance use disorder
• severe somatic illness (e.g. cancer, cardiovascular disease, instable diabetes mellitus; blood pressure ≥ 160/100 mmHg at rest and/or current treatment of hypertensive crisis within last 6 months)
• known hypersensitivity to hydrocortisone
• known glucose-galactose malabsorption
• systemic (i.v. or oral) glucocorticoid treatment within the last 3 months
• known pheochromocytoma
• Simultaneous participation in another interventional trial
• Pregnant or breastfeeding females
• current or planned psychotherapy (during the period of the study)
• known hereditary galactose intolerance
• known lactase deficiency